{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:57:22Z","timestamp":1794535042789,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K99 DA048974"],"award-info":[{"award-number":["K99 DA048974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA056660"],"award-info":[{"award-number":["R01 DA056660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA045836"],"award-info":[{"award-number":["R01 DA045836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA056365"],"award-info":[{"award-number":["R01 DA056365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP5 OD026407"],"award-info":[{"award-number":["DP5 OD026407"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.neuropharm.2024.110163","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:23:54Z","timestamp":1727367834000},"page":"110163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0616-7147","authenticated-orcid":false,"given":"Joel","family":"Bonilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0629-4882","authenticated-orcid":false,"given":"Giuseppe","family":"Giannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6904","authenticated-orcid":false,"given":"Nathaniel P.","family":"Kregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-6899","authenticated-orcid":false,"given":"Jasper A.","family":"Heinsbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4517-0543","authenticated-orcid":false,"given":"David E.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-6384","authenticated-orcid":false,"given":"Jamie","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110163_bib1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/FBP.0000000000000628","article-title":"Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats","volume":"32","author":"Berquist","year":"2021","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00213-016-4278-x","article-title":"Sex differences in reinstatement of alcohol seeking in response to cues and yohimbine in rats with and without a history of adolescent corticosterone exposure","volume":"233","author":"Bertholomey","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2018.06.039","article-title":"Polydrug use among heroin users in Cleveland, OH","volume":"192","author":"Bobashev","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2024.110163_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.110163_bib5","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1021\/jm970424c","article-title":"6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist","volume":"40","author":"Bromidge","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2024.110163_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110163_bib7","article-title":"Neural circuits controlling choice behavior in opioid addiction","volume":"226","author":"Chang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","article-title":"Polysubstance use: a broader understanding of substance use during the opioid crisis","volume":"110","author":"Cicero","year":"2020","journal-title":"Am. J. Publ. Health"},{"key":"10.1016\/j.neuropharm.2024.110163_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fnins.2020.00569","article-title":"One is not enough: understanding and modeling polysubstance use","volume":"14","author":"Crummy","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110163_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1080\/10826084.2022.2063896","article-title":"Psychosocial and drug use assessment of regular vs. Non-regular ayahuasca users in a Brazilian sample: a web-based survey","volume":"57","author":"Daldegan-Bueno","year":"2022","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.neuropharm.2024.110163_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13170","article-title":"Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis","volume":"22","author":"de Andrade Mesquita","year":"2021","journal-title":"Obes. Rev."},{"key":"10.1016\/j.neuropharm.2024.110163_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","author":"de la Fuente Revenga","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2024.110163_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-4328(00)00314-4","article-title":"The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors","volume":"118","author":"Einat","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110163_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110163_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.neuropharm.2009.05.011","article-title":"Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice","volume":"57","author":"Fletcher","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00213-017-4529-5","article-title":"Effects of 5-HT(1A), 5-HT(2A) and 5-HT(2C) receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate","volume":"234","author":"Fletcher","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41398-022-02161-z","article-title":"Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking","volume":"12","author":"Giannotti","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.110163_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(91)90474-5","article-title":"Effects and aftereffects of ibogaine on morphine self-administration in rats","volume":"195","author":"Glick","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000026474","article-title":"The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C receptor agonist (+\/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane","volume":"37","author":"Granoff","year":"1998","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib20","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a039602","article-title":"Glutamatergic systems and memory mechanisms underlying opioid addiction","volume":"11","author":"Heinsbroek","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuropharm.2024.110163_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/psymed.2023.0009","article-title":"Tabernanthalog reduces motivation for heroin and alcohol in a polydrug use model","volume":"1","author":"Heinsbroek","year":"2023","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib22","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1038\/s41467-021-25080-x","article-title":"A common limiter circuit for opioid choice and relapse identified in a rodent addiction model","volume":"12","author":"Heinsbroek","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.110163_bib23","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1007\/s00213-022-06229-y","article-title":"Contrasting effects of DOI and lisuride on impulsive decision-making in delay discounting task","volume":"239","author":"Jiang","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib25","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.110163_bib26","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110163_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2018.09.025","article-title":"Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys","volume":"840","author":"Kohut","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.addbeh.2018.05.013","article-title":"Polydrug use patterns, risk behavior and unmet healthcare need in a community-based sample of women who use cocaine, heroin or methamphetamine","volume":"85","author":"Lorvick","year":"2018","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2024.110163_bib30","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1038\/s41380-021-01159-1","article-title":"An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress","volume":"26","author":"Lu","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110163_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-012-2803-0","article-title":"Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys","volume":"225","author":"Maguire","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12926","article-title":"Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats","volume":"26","author":"Martin","year":"2021","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/7854_2017_479","article-title":"The effects of hallucinogens on gene expression","volume":"36","author":"Martin","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2024.110163_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.15288\/jsa.2006.67.529","article-title":"Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences","volume":"67","author":"McCabe","year":"2006","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.neuropharm.2024.110163_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2399","article-title":"Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism","volume":"7","author":"Meinhardt","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuropharm.2024.110163_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2022.100025","article-title":"Classic and non\u2010classic psychedelics for substance use disorder: a review of their historic, past and current research","volume":"3","author":"Mendes","year":"2022","journal-title":"Addiction Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.110163_bib37","series-title":"Neuropharmacology of Ethanol: New Approaches","first-page":"251","article-title":"Alcohol reinforcement: biobehavioral and clinical considerations","author":"Meyer","year":"1991"},{"key":"10.1016\/j.neuropharm.2024.110163_bib38","series-title":"Guide for the Care and Use of Laboratory Animals","first-page":"220","year":"2011"},{"key":"10.1016\/j.neuropharm.2024.110163_bib39","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110163_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005315","article-title":"Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors","volume":"359","author":"Nelson","year":"1999","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2024.110163_bib42","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1007\/s00213-019-05328-7","article-title":"Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice","volume":"236","author":"Oppong-Damoah","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/dar.13348","article-title":"Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: results of a large international cross-sectional survey","volume":"41","author":"Perkins","year":"2022","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neuropharm.2024.110163_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202100297","article-title":"Mile high on heroin: lessons on the opioid epidemic from the mile high city","volume":"44","author":"Peters","year":"2022","journal-title":"Bioessays"},{"key":"10.1016\/j.neuropharm.2024.110163_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/26331055211033847","article-title":"Engineering safer psychedelics for treating addiction","volume":"16","author":"Peters","year":"2021","journal-title":"Neurosci Insights"},{"key":"10.1016\/j.neuropharm.2024.110163_bib46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"1996","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2024.110163_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002130050325","article-title":"A comparison of progressive ratio schedules versus behavioral economic measures: effect of an alternative reinforcer on the reinforcing efficacy of phencyclidine","volume":"132","author":"Rodefer","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110163_bib49","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R5549","article-title":"R-(-)2,5-dimethoxy-4-iodoamphetamine (DOI) blunts the discriminative stimulus properties of oxycodone","volume":"36","author":"Salinsky","year":"2022","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2024.110163_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dcn.2014.12.002","article-title":"Adolescent rats are resistant to forming ethanol seeking habits","volume":"16","author":"Serlin","year":"2015","journal-title":"Dev Cogn Neurosci"},{"key":"10.1016\/j.neuropharm.2024.110163_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107949","article-title":"Adjunctive effect of the serotonin 5-HT(2C) receptor agonist lorcaserin on opioid-induced antinociception in mice","volume":"167","author":"Sierra","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110163_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jnc.15540","article-title":"Molecular insights into psychedelic drug action","volume":"162","author":"Slocum","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.110163_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11597520-000000000-00000","article-title":"Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals","volume":"72","author":"Tetrault","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2024.110163_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/lm.050187.119","article-title":"Acute ovarian hormone treatment in freely cycling female rats regulates distinct aspects of heroin seeking","volume":"27","author":"Vazquez","year":"2020","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2024.110163_bib55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2024.110163_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drugpo.2017.07.009","article-title":"Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users","volume":"49","author":"Wang","year":"2017","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103380","article-title":"Classic psychedelics in the treatment of substance use disorder: potential synergies with twelve-step programs","volume":"98","author":"Yaden","year":"2021","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.neuropharm.2024.110163_bib58","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuropharm.2015.09.031","article-title":"Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice","volume":"101","author":"Zhang","year":"2016","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:57:34Z","timestamp":1730865454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824003320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":58,"alternative-id":["S0028390824003320"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110163","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110163"}}